December 12, 2024
FOR IMMEDIATE RELEASE
Ladenburg Thalmann Successfully Hosts Virtual Oncology Innovators & Investors Symposium
New York, NY - December 12, 2024 - Ladenburg Thalmann & Co. Inc. today announced the successful completion of its inaugural Virtual Oncology Innovators & Investors Symposium. This exclusive one-day event brought together industry-leading companies and investors to spotlight cutting-edge advancements in oncology.
Ladenburg Thalmann biotechnology analysts meticulously selected a group of publicly traded companies at the forefront of transforming cancer treatment. The symposium featured presentations showcasing groundbreaking treatments and technologies, followed by a dynamic Q&A session moderated by Ladenburg Thalmann's esteemed biotechnology analysts, Dr. Aydin Huseynov, CFA, and Matthew Kaplan.
"We are thrilled with the success of our inaugural Virtual Oncology Innovators & Investors Symposium," said Jeffery Cohen, Director of Research. "This event provided a valuable platform for industry leaders to connect, share insights, and explore the future of oncology. We are committed to fostering meaningful dialogue within the investment community and supporting the development of innovative cancer therapies."
The symposium fostered valuable connections between key stakeholders in the oncology investment landscape, facilitating insightful discussions and driving innovation in the field.
About Ladenburg Thalmann & Co. Inc.
Ladenburg Thalmann & Co. Inc., established in 1876, is a well-established financial institution with a rich history of serving clients across various sectors. Ladenburg is a diversified financial services company that provides investment banking, equity research, institutional sales and trading, independent brokerage and advisory, and asset management.
About Dr. Aydin Huseynov, CFA
Managing Director of Biotechnology Equity Research at Ladenburg Thalmann. He specializes in biotechnology with a focus on oncology. He has 10 years of experience and has been a publishing analyst for 5 years. He earned his MBA from Duke, and his M.D. from Azerbaijan Medical University. He is a CFA charter holder and holds several FINRA licenses including Series 63, 79, and 87.
About Matthew Kaplan
Managing Director of Biotechnology Equity Research at Ladenburg Thalmann. He specializes in the Biotechnology sector. He has 30+ years of experience and has been a publishing analyst for 24+ years. He earned his BS from the University of Michigan. He holds several FINRA licenses including Series 7, 63, 86, and 87.